Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 1.40% to $18.78 Friday, on what proved to be an all-around great ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701 ...

Corbus Pharmaceuticals Holdings ( (CRBP) ) has released its Q3 earnings. Here is a breakdown of the information Corbus Pharmaceuticals Holdings ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Corbus Pharmaceuticals Holdings ( NASDAQ:CRBP) stock is up 478% in the last year, providing strong gains for ...

Corbus Pharmaceuticals (CRBP) presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricted CB1 inverse agonist. The data are being ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus” or the "Company”), an oncology and obesity company with a diversified portfolio, presents new ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a ...

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private ...